1 / 11

May 2013

May 2013. About The Company. International patents have been granted on a platform implant technology that addresses three markets:. The Global Dental Implants Market The Global Orthopaedic Implant Market Veterinary Implantology.

sauda
Télécharger la présentation

May 2013

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. May 2013

  2. About The Company International patents have been granted on a platform implant technology that addresses three markets: The Global Dental Implants Market The Global Orthopaedic Implant Market Veterinary Implantology The global dental implants market is forecasted to grow at 6% (CAGR) from $3.2 billion in 2010 to $4.2 billion in 2015 (Sandler Research, Nov., 2010).

  3. Value Proposition – Dental Implant SIT Implant Current Implant (Double Stem design) (Single post design) • Uses existing comparable metals • Less prone to failure (double stem) • Lower Cost • No damage to bone (no cutting or crushing) • Angled rings simplify insertion and fixation • Superior in resisting torque (turning) • Removes less tissue • Easily Installed / single precision placement • Enhanced opportunity for dentists (GP’s) • Prone to failure (falling out) • Rotates due to single post • High costs of screw implants • Complex process for dentists (GP’s) • Lengthy patient waiting time

  4. Market Needs and Assessment Competitive Advantage Growth Market Limited Entry Barriers Market Expansion

  5. Funding Requirements and Uses Uses of Funds * Funding Amount: • $3.77 million total equity funding sought • Ideally in tranches of $500K to $1.0M from each investor to coincide with cash flow timing. • Partial funding from warrants exercised • Residual funding by non-dilutive government grants Means: • Preferred Shares (convertible) with common share purchase warrants @ $10.00 per share • Warrants – 2 common shares for each Preferred share @ $7.50 per share • Warrants are detachable and transferrable • Bonus Shares – 1 common share for each Preferred • Bonus Shares – 1 common share for each warrant exercised and common share purchased • Funding to Q4 – 2015, all other costs offset by cash flows from future revenues • ** Consists of 5 personnel at average $132K per annum (base)

  6. Critical Path Q3-Q4 2012 | Q4 2012–Q1 2013 | Q1 2013-Q2 2014 | Q1 2014-Q1 2015 | Q4 2014 Canada Q1 2015 FDA * Licensing discussions begin Q1 2013

  7. Financial Highlights NPV (after-tax) of $47.7M (Independent third party valuation) Projected Value per share of $40.78 (June 2017)

  8. Markets & Revenues Conservative projections based on .08% of global market volume of $4.2 billion (2015)

  9. Projected ROI & Exit Strategy Return on Investment • NPV of $47.7M (independent valuation) • Projected Value per share of $40.78 (June 2017) • Possible IPO in five years • Possible divesting of whole company or just dental asset as development continues on the orthopaedic and veterinary applications * Assumes 50% of warrant shares exercised ** Anticipated distribution of Licensing revenues

  10. Professional Team • Scientific Advisors • Dr. Emmanuel Rajczak, DDS • Dr. Greg Wohl, Ph.D. – Biomedical Engineering, McMaster University • Dr. Karl Stobbe, M.D., Regional Assistant Dean, Michael G. DeGroote, School of Medicine, McMaster University • Dr. Robert Josefchak– Orthopaedic Surgeon, McMaster University Management Team • Christopher Ostrovski, President & CEO • Dr. Michael Lococo, Director Innovation • Doug McNaughton, CFO • Martin Lococo, Director Marketing & Sales • Diane Kalina, Director Licensing • Corporate Consultants • Dr. Scott Proctor - PG Business Growth Advisors and Certified Public Accounts, LLC • Wendy Hill - GAP Strategies • Daryl Wisdahl – EMERGO Group • Diane Kalina – BioCatalyst Yorkton Ltd. • Bonnie Loubert – Loubert Brown Consulting • Corporate Advisors • Gowling, Henderson, LeFluer (Patents) • Gardiner-Roberts LLP (Corporate Attorneys) • Deloitte Touche – (Auditors) • Randy Gillen - Licensing

  11. Contact information • Christopher Ostrovski, President & CEO costrovski@stemmedimplant.com Tel. 416 – 626 – 1835 ( Canada ) • Douglas McNaughton, CFO dmcnaughton@stemmedimplant.com Tel. 289 -213-8886 ( Canada ) • www.stemmedimplant.com

More Related